Structured Abstract
Introduction Large-language models can help extract information from clinical notes, making them potentially useful for research in ulcerative colitis. However, it remains unclear if these models will scale well in practice.
Methods We analyzed the performance and cost of programmatically using GPT-4 to abstract Mayo endoscopic subscores (MES) from 499 colonoscopy reports using different prompting strategies.
Results Zero-shot prompting, where GPT-4 is instructed without examples, was most accurate (83.55%) and cost-effective ($0.097/note).
Discussion Using GPT-4 to automatically curate the MES and other variables is a practical strategy for quantifying UC activity and measuring improvements to clinical care.
Competing Interest Statement
VAR receives research support from Alnylam, Takeda, Merck, Genentech, Blueprint Medicines, Stryker, Mitsubishi Tanabe, and Janssen. He also is a shareholder of ZebraMD. RPY has nothing to disclose.
Funding Statement
Research reported in this publication was supported by the National Library of Medicine of the National Institutes of Health under Award Number K99LM014099, the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1 TR001872, as well as the UCLA Clinical and Translational Science Institute through grant number UL1TR001881. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. This research project has benefitted from the Microsoft Accelerate Foundation Models Research (AFMR) grant program through which leading foundation models hosted by Microsoft Azure along with access to Azure credits were provided to conduct the research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of UCSF waived ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Financial/Grant Support Research reported in this publication was supported by the National Library of Medicine of the National Institutes of Health under Award Number K99LM014099, the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number UL1 TR001872, as well as the UCLA Clinical and Translational Science Institute through grant number UL1TR001881. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. This research project has benefitted from the Microsoft Accelerate Foundation Models Research (AFMR) grant program through which leading foundation models hosted by Microsoft Azure along with access to Azure credits were provided to conduct the research.
Conflicts of Interest: VAR receives research support from Alnylam, Takeda, Merck, Genentech, Blueprint Medicines, Stryker, Mitsubishi Tanabe, and Janssen. He also is a shareholder of ZebraMD. RPY has nothing to disclose.
Writing Assistance: None.
Data Availability
All data is PHI-compliant and is not to be publicly available.
